摘要
目的通过观察患儿的临床表现,探讨分析孟鲁司特钠辅助治疗儿童支原体肺炎的可行性。方法选取2014年8月~2016年7月在我院接受治疗的62例支原体肺炎患儿作为研究对象,按照随机数字表法将其分为对照组(n=30)和观察组(n=32)。对照组患儿采用阿奇霉素静滴和布地奈德雾化吸入的方法进行治疗,观察组患儿在对照组治疗方法的基础上增加孟鲁司特钠口服的方法进行治疗。观察记录两组患儿的相关临床指标数据,包括治疗总有效率、相关症状缓解时间、住院时间、并发症发生率、血气分析情况等。结果观察组患儿的治疗总有效率显著高于对照组,差异有统计学意义(P<0.05)。观察组患儿的咳嗽、体温下降、啰音消失和住院时间均短于对照组,且肺外并发症的发生率也低于对照组,差异均有统计学意义(P<0.05)。观察组患儿治疗后的一秒用力呼气容积(FEV1)、FEV1/用力肺活量(FVC)、最大呼气流量(PEF)均高于对照组,差异有统计学意义(P<0.05)。观察组患儿治疗后的氧分压(PO2)含量高于对照组,二氧化碳分压(PCO2)含量低于对照组,差异有统计学意义(P<0.05)。结论在治疗儿童支原体肺炎时,孟鲁司特钠具有显著效果,可有效推进患儿的治疗进程,改善相关临床症状,促使患儿的肺功能得到恢复,且具有较高的安全性,因而可在临床上进行推广应用。
Objective To investigate the feasibility of Montelukast Sodium as an adjuvant treatment in children with Mycoplasma pneumonia by observing their clinical manifestations.Methods Sixty-two children with Mycoplasma pneumonia who were treated in our hospital from August 2014 to July 2016 were selected as subjects.They were divided into the control group(n=30)and observation group(n=32)according to the random number table method.In the control group,pediatric patients were treated with intravenous infusion of Azithromycin and aerosol inhalation of Budesonide,while in the observation group,on the basis of the control group,Montelukast Sodium as oral administration was added.The relative clinical data including total therapeutic effectiveness rate,remission time of relevant symptoms,hospital stay,incidence of complications,and blood gas analysis were observed and recorded in the two groups.Results The therapeutic effectiveness rate in the observation group was significantly higher than that of the control group,and the difference was statistically significant(P<0.05).The remission time of cough,temperature lowering,disappearance of rales and hospital stay in the observation group were all shorter compared with those in the control group,the incidence of extrapulmonary complications was also lower than that of the control group,and the differences were statistically significant(P<0.05).The forced expiratory volume in one second(FEV1),the forced expiratory volume in one second/forced vital capacity(FEV1/FVC),maximum expiratory flow(PEF)were all superior to those in the control group,and the differences were statistically significant(P<0.05).The content of PO2 in the observation group was higher than that in the control group,and the content of PCO2 was lower than that in the control group,which were displayed statistical significance(P<0.05).Conclusion In the treatment of children with Mycoplasma pneumonia,Montelukast Sodium can obtain a remarkable effect by greatly promoting therapeutic progress and improving the relevan
作者
陶梦婕
TAO Meng-jie(Department of Pediatrics,the Second People′s Hospital of Longgang District,Guangdong Province,Shenzhen 518112,China)
出处
《中国当代医药》
2018年第10期147-149,153,共4页
China Modern Medicine
关键词
孟鲁司特钠
小儿
支原体肺炎
辅助治疗
Montelukast Sodium
Children
Mycoplasma pneumonia
Adjuvant therapy
